Polygenic Score (PGS) ID: PGS012582

Predicted Trait
Reported Trait Cholelithiasis
Mapped Trait(s) cholelithiasis (MONDO_0012672)
Released in PGS Catalog: June 17, 2026
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name PRS13_cholelithiasis
Development Method
Name Pruning and Thresholding (P+T)
Parameters p ≤ 5 × 10−6, r2 < 0.001
Variants
Original Genome Build NR
Number of Variants 13
Effect Weight Type beta
PGS Source
PGS Catalog Publication (PGP) ID PGP000816
Citation (link to publication) Mi N et al. Prev Med (2024)
Ancestry Distribution
Source of Variant
Associations (GWAS)
European: 100%
367,944 individuals (100%)
PGS Evaluation
European: 100%
1 Sample Sets

Development Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry Cohort(s)
Europe PMC: 36653562
[
  • 37,041 cases
  • , 330,903 controls
]
 European
(Finnish)		 FinnGen

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM030739 PSS012273|
European Ancestry|
317,640 individuals
 PGP000816 |
Mi N et al. Prev Med (2024)
 Reported Trait: cholelithiasis — — Hazard ratio (HR, high vs low tertile): 1.24 [1.16, 1.32] age, sex, UK Biobank assessment centers, and additionally adjusted for index of multiple deprivation, overall health rating, long-standing illness, obesity, dyslipidemia for triglycerides, dyslipidemia for high-density lipoprotein cholesterol, hypertension, hyperglycemia, multivitamin use, mineral use, aspirin use, non-steroidal anti-inflammatory drugs use, statin use, proton pump inhibitors use, lifestyle factors (diet, smoking, alcohol consumption, coffee consumption, physical activity and body weight) —
PPM030740 PSS012273|
European Ancestry|
317,640 individuals
 PGP000816 |
Mi N et al. Prev Med (2024)
 Reported Trait: cholelithiasis x lifestyle interaction — — Hazard ratio (HR, unfavorable lifestyle and high PRS vs. favorable lifestyle and low PRS): 1.98 [1.67, 2.35] cerides, dyslipidemia for high-density lipoprotein cholesterol, hypertension, hyperglycemia, multivitamin use, mineral use, aspirin use, non-steroidal anti-inflammatory drugs use, statin use and proton pump inhibitors use —

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS012273 — Median = 12.7 years
[
  • 11,017 cases
  • , 306,623 controls
]
,
48.1 % Male samples
 Mean = 56.7 years
Sd = 7.97 years		 European — UKB —